²úÆ·¿ÆÆÕ | ÄÔ´úл¸ÄÉÆÒ©¡ª¡ªßÁÀÎ÷̹Ƭ
ʱ¼ä£º
2024-10-11
ßÁÀÎ÷̹£¨Piracetam£©£¬£¬£¬£¬£¬£¬£¬£¬ÊÇÒ»ÖÖÄÜ×÷ÓÃÓÚÈÏÖª¹¦Äܶø²»»áÒýÆðÕò¾²»ò´Ì¼¤ÐÔ×÷ÓõÄÒ©Î£¬£¬£¬£¬£¬£¬£¬²¢¹ã·ºÓ¦ÓÃÓÚÖÐÊàÉñ¾ÏµÍ³¼²²¡ÖÎÁÆÖС£¡£¡£¡£¡£
»îÐԳɷݣºßÁÀÎ÷̹
»¯Ñ§Ãû³Æ£º2-Ñõ´ú-1-ßÁ¿©Íé»ùÒÒõ£°·

·Ö×Óʽ£ºC6H10N2O2
·Ö×ÓÁ¿£º142.16
ßÁÀÎ÷̹µÄ
·¢Õ¹±³¾°
20ÊÀ¼Í60Äê´ú£¬£¬£¬£¬£¬£¬£¬£¬GABA±»Ö¤ÊµÊÇÒ»ÖÖÖØÒªµÄÄÔÉñ¾µÝÖÊÒÖÖÆ¼Á£¬£¬£¬£¬£¬£¬£¬£¬ÊÇÒ»ÖÖÓë˯ÃßÓйصÄÖØÒªµÄÒÖÖÆÐÔÉñ¾µÝÖÊ£¬£¬£¬£¬£¬£¬£¬£¬ÕâÒýÆðÁËÈËÃǵĸ߶ÈÖØÊÓ£¬£¬£¬£¬£¬£¬£¬£¬ÓëGABAÏà¹ØµÄÒ©Àíѧ±»ÒýÈëҩѧ¹¤Òµ¡£¡£¡£¡£¡£
1964Ä꣬£¬£¬£¬£¬£¬£¬£¬±ÈÀûʱÓÅʱ±È(UCB)ÖÆÒ©¹«Ë¾ºÏ³ÉÁ˦Ã-°±»ù¶¡Ëá(GABA)µÄ»·×´ÑÜÉúÎïßÁÀÎ÷̹(1,Piracetam)£¬£¬£¬£¬£¬£¬£¬£¬Ä⿪·¢Æä³ÉΪÕò¾²Ò©£¬£¬£¬£¬£¬£¬£¬£¬È»¶ø¸ÃÒ©ËäÈ»ÓëGABAÏà¹Ø£¬£¬£¬£¬£¬£¬£¬£¬µ«ËüÈ´²»Ö±½ÓÓ°ÏìGABAÊÜÌ壬£¬£¬£¬£¬£¬£¬£¬Ò²Ã»ÓÐÓÕµ¼Ë¯ÃßµÄ×÷Ó㬣¬£¬£¬£¬£¬£¬£¬Ïà·´£¬£¬£¬£¬£¬£¬£¬£¬Giurgea²©Ê¿È´·¢ÏÖ¸ÃÒ©Äܹ»Ìá¸ßÈËÃǵÄÈÏÖªÄÜÁ¦¡£¡£¡£¡£¡£
1971Ä꣬£¬£¬£¬£¬£¬£¬£¬¾¹ýÉñ¾Ò©Àíѧ¼Ò¡¢»¯Ñ§¼ÒGiurgea²©Ê¿¼á³Ö²»Ð¸µÄÑо¿£¬£¬£¬£¬£¬£¬£¬£¬µÚ1¸ö¾ßÓдÙÖÇ»îÐÔµÄÎ÷̹ÀàÒ©Î¡ªßÁÀÎ÷̹ÕýʽÉÏÊС£¡£¡£¡£¡£
1972Ä꣬£¬£¬£¬£¬£¬£¬£¬Giurgea²©Ê¿Ò²¸ù¾ÝßÁÀÎ÷̹Ìá³öÁË¡°´ÙÖÇÒ©£¨nootrope£©¡±µÄ¸ÅÄî¡£¡£¡£¡£¡£¡°nootrope¡±Ò»´Ê£¬£¬£¬£¬£¬£¬£¬£¬Ô´×ÔÏ£À°Ó¡ª noos´ú±í´ÏÃ÷µÄ£¬£¬£¬£¬£¬£¬£¬£¬tropein´ú±íÓÐÀûµÄ[1]¡£¡£¡£¡£¡£
ÏÖÔÚ£¬£¬£¬£¬£¬£¬£¬£¬ßÁÀÎ÷̹±»¹ã·ºÈÏΪÊÇÒ»ÖÖÄÔ´úл¸ÄÉÆÒ©£¬£¬£¬£¬£¬£¬£¬£¬Ö÷ÒªÓÃÓÚÖÎÁƼ±¡¢ÂýÐÔÄÔѪ¹Ü²¡¡¢ÄÔÍâÉË¡¢¸÷ÖÖÖж¾ÐÔÄÔ²¡µÈ¶àÖÖÔÒòËùÖµļÇÒä¼õÍ˼°Çá¡¢ÖжÈÄÔ¹¦ÄÜÕϰ¡£¡£¡£¡£¡£Ò²¿ÉÓÃÓÚ¶ùͯÖÇÄÜ·¢Óý³Ù»º¡£¡£¡£¡£¡£
¶à°Ðµã
¸ÄÉÆÄÔ´úл

ÔÚÉñ¾ÔªË®Æ½ÉÏ£¬£¬£¬£¬£¬£¬£¬£¬ßÁÀÎ÷̹µ÷½ÚһϵÁеÝÖÊϵͳ£¨°üÀ¨µ¨¼îÄܺ͹Ȱ±ËáÄÜ£©µÄÉñ¾´«µÝ£¬£¬£¬£¬£¬£¬£¬£¬¾ßÓÐÉñ¾±£»£»£»£»£»£»£»£»¤ÐÔ£¬£¬£¬£¬£¬£¬£¬£¬²¢¸ÄÉÆÉñ¾¿ÉËÜÐÔ£»£»£»£»£»£»£»£»ÔÚѪ¹ÜˮƽÉÏ£¬£¬£¬£¬£¬£¬£¬£¬ßÁÀÎ÷̹¿ÉÒÔ¼õÉÙºìϸ°ûÓëѪ¹ÜÄÚÆ¤µÄÕ³¸½£¬£¬£¬£¬£¬£¬£¬£¬·ÀֹѪ¹Ü¾·ÂΣ¬£¬£¬£¬£¬£¬£¬£¬´Ù½øÎ¢Ñ»·[2]¡£¡£¡£¡£¡£
ßÁÀÎ÷̹µÄ
ÁÙ´²Ó¦ÓÃ
ÈÏÖª¹¦ÄÜÕϰ
±ÈÀûʱµÄÑо¿ÈËÔ±¶Ô19Ïî˫ä¡¢°²Î¿¼Á¶ÔÕÕµÄÑо¿½øÐÐÁË·ÖÎö£¬£¬£¬£¬£¬£¬£¬£¬Ñо¿¶ÔÏóÊÇ»¼ÓгմôÖ¢»òÈÏÖªÕϰµÄ»¼Õß¡£¡£¡£¡£¡£ÕâÏîÜöÝÍ·ÖÎöµÄ½á¹ûÖ¤Ã÷ÁËʹÓÃßÁÀÎ÷̹ºÍʹÓð²Î¿¼ÁµÄÈËÖ®¼ä´æÔÚ²îÒ죬£¬£¬£¬£¬£¬£¬£¬³¬¹ý60%µÄ½ÓÊÜßÁÀÎ÷̹ÖÎÁƵϼÕßÔÚCGICÆÀ·ÖÖÐÓиÄÉÆ£¬£¬£¬£¬£¬£¬£¬£¬Ò²¾ÍÊÇ˵½á¹ûÊÇÕýÏòµÄ£¬£¬£¬£¬£¬£¬£¬£¬±íÃ÷ßÁÀÎ÷̹ÔÚ¸ÄÉÆÈÏÖªÕϰ·½ÃæµÄÒæ´¦£¬£¬£¬£¬£¬£¬£¬£¬ÎªÖ¤ÊµßÁÀÎ÷̹ÓÃÓÚ²»Í¬ÈÏÖªÕϰÈËȺµÄÓÐЧÐÔÌṩÁËÖ¤¾Ý[3]¡£¡£¡£¡£¡£

Áµ¶ÐÍϸ°ûƶѪ²¡
Áµ¶ÐÍϸ°ûƶѪ²¡ÊÇÒ»ÖÖÓÉÒì³£»£»£»£»£»£»£»£»òÁ״Ѫºìµ°°×ÒýÆðµÄÒÅ´«ÐÔ¼²²¡£¡£¡£¡£¡£¬£¬£¬£¬£¬£¬£¬£¬ÕâЩ»¼Õߵĺìϸ°û¸üÈÝÒ×Õ³¸½ÔÚÄÚÆ¤±ÚÉÏ¡£¡£¡£¡£¡£ÕâÖÖºìϸ°ûÕ³¸½ÇãÏòÓÚ×èÈûëϸѪ¹ÜѪÁ÷£¬£¬£¬£¬£¬£¬£¬£¬µ¼Ö¾ֲ¿×éÖ¯ËðÉ˺ÍÌÛÍ´£¬£¬£¬£¬£¬£¬£¬£¬³ÆÎªÁ״ϸ°ûΣÏ󡣡£¡£¡£¡£ßÁÀÎ÷̹¶Ôºìϸ°û²úÉúÁ˶àÖÖÓ°Ï죬£¬£¬£¬£¬£¬£¬£¬Ê¹Æä³ÉΪÖÎÁÆÕâÖÖ¼²²¡µÄDZÔÚºòѡҩÎï¡£¡£¡£¡£¡£Ò»·Ý·¢±íÔÚ¡¶ÁøÒ¶µ¶¡·ÉϵÄÑо¿ÏÔʾ£¬£¬£¬£¬£¬£¬£¬£¬ßÁÀÎ÷̹ÖÎÁÆÁµ¶ÐÍϸ°ûƶѪ²¡ÓÐЧ£¬£¬£¬£¬£¬£¬£¬£¬ÇÒÎÞ¸±×÷ÓÃ[4]¡£¡£¡£¡£¡£
³ý´ËÖ®Í⣬£¬£¬£¬£¬£¬£¬£¬ßÁÀÎ÷̹ÔÚÖÎÁÆÀÏÄê³Õ´ô¡¢Ñ£ÔΡ¢Öз硢¶ùͯÔĶÁÕϰµÈ¶¼ÏÔʾ³öÓÐЧÐÔ¡£¡£¡£¡£¡£
×ܽá
ßÁÀÎ÷̹ÊÇÒ»ÖÖ¸ÄÉÆÄÔ´úлÀàÒ©Î£¬£¬£¬£¬£¬£¬£¬ÆäÒ©Àí»úÖÆÈÔÔÚ²»¶Ï̽Ë÷ÖУ¬£¬£¬£¬£¬£¬£¬£¬Ä¿Ç°µÄÑ֤ҽѧ֤¾ÝÒѾ±íÃ÷Æä¾ßÓиÄÉÆÉñ¾Ôª¹¦ÄÜ¡¢¸ÄÉÆÎ¢Ñ»·µÄ×÷Ó㬣¬£¬£¬£¬£¬£¬£¬ßÁÀÎ÷̹ÉÏÊÐÖÁ½ñÒÑ50ÓàÄ꣬£¬£¬£¬£¬£¬£¬£¬Òѹ㷺ӦÓÃÓÚÈÏÖª¹¦ÄÜÕϰºÍÄÔѪ¹Ü¼²²¡µÈµÄÁÙ´²ÖÎÁÆ£¬£¬£¬£¬£¬£¬£¬£¬ÇÒ¾ßÓнϺÃÖÎÁÆÐ§¹û¡£¡£¡£¡£¡£
²Î¿¼ÎÄÏ×
[1] ËÎÑÞÁá,Ëï»¶,Àî°ØÄÈ.Î÷̹ÀàÒ©ÎïÑо¿½øÕ¹[J].ÖйúÒ©Òµ,2015,24(01):4-7.
[2] Winblad B. Piracetam: a review of pharmacological properties and clinical uses. CNS Drug Rev. 2005 Summer;11(2):169-82.
[3] Waegemans T, Wilsher CR, Danniau A, Ferris SH, Kurz A, Winblad B. Clinical efficacy of piracetam in cognitive impairment: A meta-analysis. Dement Geriatr Cogn Disord 2002;13:217¨C224.
[4] de Araujo JT, Nero GS. Piracetam and acetamide in sickle-cell disease. Lancet. 1977 Aug 20;2(8034):411. PMID: 70630.
ÌØ±ð˵Ã÷£º±¾ÎÄÄÚÈݲ¿·ÖÀ´Ô´ÒÔÉϲο¼ÎÄÏ×£¬£¬£¬£¬£¬£¬£¬£¬½ö×öÐÅÏ¢ÕûºÏ·ÖÏí£¬£¬£¬£¬£¬£¬£¬£¬²»´ú±íÈκÎÓÃÒ©½¨Ò飬£¬£¬£¬£¬£¬£¬£¬ÈçÓÐÇÖȨ¡¢ÐÅÏ¢ÓÐÎó»òÆäËûÒìÒ飬£¬£¬£¬£¬£¬£¬£¬ÇëÁªÏµÆ½²©¹ú¼ÊÌåÓý¹ÙÍø½øÐÐɾ³ý£¡
Ïà¹ØÐÂÎÅ